Molecular Cancer Therapeutics

Systemic Checkpoint Blockade by PD-L1 Single-Chain Antibody Confers Potent Antitumor Immunity and Long-term Survival.  21:1710-1721. 2022

[⁸⁹Zr]ZrDFO-CR011 PET Correlates with Response to Glycoprotein Nonmetastatic Melanoma B–targeted Therapy in Triple-negative Breast Cancer.  21:440-447. 2022

Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1–Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.  21:347-358. 2022

Strategies in overcoming homologous recombination proficiency and PARP inhibitor resistance.  20:1542-1549. 2021

Gene expression signature correlates with outcomes in metastatic renal cell carcinoma patients treated with everolimus alone or with a vascular disrupting agent.  20:1454-1461. 2021

Neutralization of TGFβ improves tumor immunity and reduces tumor progression in ovarian carcinoma.  20:602-611. 2021

RANKL-targeted combination therapy with osteoprotegerin variant devoid of trail binding exerts biphasic effects on skeletal remodeling and antitumor immunity.  19:2585-2597. 2020

Comparison of panitumumab-IRDye800CW and 5-aminolevulinic acid to provide optical contrast in a model of glioblastoma multiforme.  19:1922-1929. 2020

CHK1/2 inhibitor prexasertib suppresses notch signaling and enhances cytotoxicity of cisplatin and radiation in head and neck squamous cell carcinoma.  19:1279-1288. 2020

Identification of ALDH1A3 as a viable therapeutic target in breast cancer metastasis-initiating cells.  19:1134-1147. 2020

B-arrestins regulate stem cell-like phenotype and response to chemotherapy in bladder cancer.  18:801-811. 2019

Prognostic and biologic relevance of clinically applicable long noncoding RNA profiling in older patients with cytogenetically normal acute myeloid leukemia.  18:1451-1459. 2019

Retraction: γ-tocotrienol promotes trail-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/P53–mediated upregulation of death receptors (Molecular Cancer Therapeutics (2010) 9 (2196–207) DOI: 10.1158/1535-7163.MCT-10-0277).  17:2072. 2018

Nuclear factor-kb promotes urothelial tumorigenesis and cancer progression via cooperation with androgen receptor signaling.  17:1303-1314. 2018

Trastuzumab-resistant HER2 ^þ breast cancer cells retain sensitivity to poly (adp-ribose) polymerase (parp) inhibition.  17:921-930. 2018

Histone methyltransferase ezh2: A therapeutic target for ovarian cancer.  17:591-602. 2018

JQ1 induces DNA damage and apoptosis, and inhibits tumor growth in a patient-derived xenograft model of cholangiocarcinoma.  17:107-118. 2018

Combining Chk1/2 inhibition with cetuximab and radiation enhances in vitro and in vivo cytotoxicity in head and neck squamous cell carcinoma.  16:591-600. 2017

Preclinical evaluation of UAB30 in pediatric renal and hepatic malignancies.  15:911-921. 2016

SPARC-independent delivery of nab-paclitaxel without depleting tumor stroma in patient-derived pancreatic Cancer xenografts.  15:680-688. 2016

The TMPRSS2-ERG gene fusion blocks XRCC4-mediated nonhomologous end-joining repair and radiosensitizes prostate cancer cells to PARP inhibition.  14:1896-1906. 2015

Preclinical evaluation of a novel RXR agonist for the treatment of neuroblastoma.  14:1559-1569. 2015

Efficacy of carboplatin alone and in combination with ABT888 in intracranial murine models of BRCA-mutated and BRCA-wild-type triple-negative breast cancer.  14:920-930. 2015

Tumor-suppressor role of notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological induction.  14:499-512. 2015

Effect of niclosamide on basal-like breast cancers.  13:800-811. 2014

Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.  12:2110-2120. 2013

Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924.  12:1958-1967. 2013

Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress wnt/β-catenin signaling.  12:1848-1858. 2013

Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and suppresses cell growth.  12:1276-1287. 2013

A novel sulindac derivative inhibits lung adenocarcinoma cell growth through suppression of Akt/mTOR signaling and induction of autophagy.  12:663-674. 2013

Smoking induces epithelial-to-mesenchymal transition in non-small cell lung cancer through HDAC-mediated downregulation of E-cadherin.  11:2362-2372. 2012

Therapeutic potential of AZD1480 for the treatment of human glioblastoma.  10:2384-2393. 2011

3,5-bis(2,4-difluorobenzylidene)-4-piperidone, a novel compound that affects pancreatic cancer growth and angiogenesis.  10:2146-2156. 2011

Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy.  9:2536-2544. 2010

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: Evidence from a xenograft study.  9:1525-1535. 2010

Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth.  9:429-437. 2010

γ-Tocotrienol promotes TRAIL-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/p53-mediated upregulation of death receptors.  9:2196-2207. 2010

Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G.  8:3331-3340. 2009

Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines.  8:3009-3014. 2009

Experimental cancer therapy using restoration of NAD⁺-linked 15-hydroxyprostaglandin dehydrogenase expression.  8:3130-3139. 2009

Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor.  8:1270-1279. 2009

Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3β.  8:914-920. 2009

The small organic compound HMN-176 delays satisfaction of the spindle assembly checkpoint by inhibiting centrosome-dependent microtubule nucleation.  8:592-601. 2009

Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors.  8:350-356. 2009

CXCR4-gp120-IIIB interactions induce caspase-mediated apoptosis of prostate cancer cells and inhibit tumor growth.  8:178-184. 2009

Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene.  7:2845-2854. 2008

Chemoprevention by perillyl alcohol coupled with viral gene therapy reduces pancreatic cancer pathogenesis.  7:2042-2050. 2008

TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth.  6:3198-3207. 2007

Enterolactone induces apoptosis in human prostate carcinoma LNCaP cells via a mitochondrial-mediated, caspase-dependent pathway.  6:2581-2590. 2007

The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion.  6:2449-2457. 2007

Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts.  6:1230-1238. 2007

High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts.  6:866-875. 2007

Inactivation of glycogen synthase kinase-3β, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells.  6:1151-1158. 2007

Treatment of prostate cancer with Ad5/3Δ24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo.  6:742-751. 2007

Antiangiogenic activity of 4′-thio-β-D-arabinofuranosylcytosine.  5:2218-2224. 2006

Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.  5:2310-2316. 2006

Silymarin inhibits UV radiation-induced immunosuppression through augmentation of interleukin-12 in mice.  5:1660-1668. 2006

Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy.  5:1577-1584. 2006

Interleukin-12-deficient mice are at greater risk of UV radiation-induced skin tumors and malignant transformation of papillomas to carcinomas.  5:825-832. 2006

ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells.  4:910-917. 2005

Characterization of inhibitors of specific carboxylesterases: Development of carboxylesterase inhibitors for translational application.  3:903-909. 2004

Telomerase inhibition by retinoids precedes cytodifferentiation of leukemia cells and may contribute to terminal differentiation.  3:1003-1009. 2004

SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility.  3:737-745. 2004

The novel estrogen 17α-20Z-21-[(4-amino)phenyl]-19-norpregna-1,3,5(10),20-tetraene-3, 17β-diol induces apoptosis in prostate cancer cell lines at nanomolar concentrations in vitro.  3:587-595. 2004

Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures.  3:437-449. 2004

Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.  2:1171-1181. 2003

Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: Implications for a dual modality treatment using capecitabine and irradiation.  1:1139-1145. 2002

Transforming growth factor β mimetics: Discovery of 7-[4-(4-cyanophenyl) phenoxy]-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase.  1:759-768. 2002

p53 mediates DNA damaging drug-induced apoptosis through a caspase-9-dependent pathway in SH-SY5Y neuroblastoma cells.  1:679-686. 2002

A model system for the design of armed replicating adenoviruses using p53 as a candidate transgene.  1:321-328. 2002